Summit Therapeutics Says Ivonescimab Data Were Presented At 2024 ESMO Annual Meeting, Including Two Presentations And One Poster Featuring Updated Ivonescimab Data In Advanced Triple-negative Breast Cancer, Recurrent/Metastatic Head And Neck Squamous...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.